1Ansquer Y, Leblanc E, Clough K, et al. Neoadjuvant chemotherapy forunresectable ovarian carcinoma: a French multicenter study. Cancer,2001,91:2329-2334.
2Kim S,Takahashi H, Lin WW, et al. Carcinoma-produced factors acti- vate myeloid cells through TLR2 to stimulate metastasis [J ]. Nature, 2009,457 ( 7225 ) : 102 - 106.
3Lee SJ, Kim BG, Lee GW, et al. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian caficer who are inadequate for optimum primary sur- gery[ J]. Obstet Gynaecol,2006,32( 1 ) :99-106.
4Li FY,Ren XB,Xie XY, et al. Meta-analysis of excision repair cross- eomplementation group 1 ( ERCCI ) association with response to plati- num-based chemotherapy in ovarian cancer[ J]. Asian Pac J Cancer Prey,2013,14(12) :7203-7206.
5Li Y,Sun X,Zhang Y, et al. Morphine promotes apoptosis via TLR2, and this is negatively regulated by β-arrestin 2 [ J ]. BBRC ,2009,378 (4) :857-861.
